Zoran (ZRAN) up strongly on Friday’s upgrade by JP Morgan.

Teva Pharmaceuticals (TEVA) has obtained two approvals from the US Food and Drug Administration for a generic version of Pfizer’s (PFE) Ellence Injection and tentative approval for a generic version of Pfizer’s Revatio Tablets.

Scopus Networks (SCOP) advised shareholders to reject the increased partial cash tender offer by Optibase (OBAS) citing that the premium was just too low. Read IsraelNewsletter’s review of Optibase’ investment strategy in Optibase: Hi-Tech Innovator or Aspiring Investment Advisor.

Nice Systems (NICE) upgraded by First Analysis Securities. Israel’s Nice Systems, a pioneer in security solutions for email and the telephone, is poised to meet if not exceed expectations for the next few years and has opportunities to penetrate follow-on software and VOIP upgrades.

Morgan Stanley sees a 4.75% - 5% interest rate by end of 2007. Globes has a good summary of the story. Bank of Israel Deputy Governor Zvi Eckstein said this week in an interview with “Globes” that he saw rates rising to a nominal 5% by the end of the year.

Oracle’s (ORCL) CEO, Larry Ellison was in Israel this week. Globes covers the story. One of Ellison’s salient points: Israel’s technology sector has matured to the point that it needs to begin looking to cheaper sources of research services. Also, see the video of Ellison speaking about Israel.

Pharmos (PARS) cutting Israel workforce as R&D expenses increased.

Share with others:

Related posts

• No related posts.